Printer Friendly

Mylan Inc unveils FDA approved Thiamine Hydrochloride Injection.

M2 EQUITYBITES-June 29, 2012-Mylan Inc unveils FDA approved Thiamine Hydrochloride Injection(C)2012 M2 COMMUNICATIONS

Pharmaceutical company Mylan Inc (NasdaqGS:MYL) reported on Thursday the receipt of final approval for its Abbreviated New Drug Application (ANDA) for preservative-free Thiamine Hydrochloride Injection, 100 mg/mL, packaged in 200 mg/2 mL multiple-dose vials.

This approval was awarded by the US Food and Drug Administration (FDA) to the company's Mylan Institutional business.

The company added Thiamine Hydrochloride Injection is indicated for the treatment of thiamine deficiency.

According to IMS Health, Thiamine Hydrochloride Injection, 100 mg/mL, had U.S. had sales of approximately USD18.6m for the 12 months ending 31 March 2012.

Effective immediately, the company is shipping this product in 25-vial packs.

((Comments on this story may be sent to>PDJune 29, 2012>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 29, 2012
Previous Article:Heartland Bancshares announces shareholders' approval for merger with Horizon Bancorp.
Next Article:Point Grey introduces new USB 3.0 camera.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters